Helicobacter pylori-negative / API2-MALT1 translocation-negative low-grade MALT lymphoma
| Autor: | Hanzo Kurosaka, Masashi Fukayama, Nobuyuki Shimizu, Naoki Hiki, Susumu Aikou, Hirokazu Yamaguchi, Koji Nozaki, Ken-ichi Mafune, Aya Shinozaki, Michio Kaminishi, Sachiyo Nomura, Keisuke Kubota, Nao Yoshizawa |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Oncogene Proteins Fusion Chromosomal translocation Gastroenterology Translocation Genetic immune system diseases Stomach Neoplasms hemic and lymphatic diseases Internal medicine Gastroscopy medicine Humans Aged medicine.diagnostic_test biology Helicobacter pylori business.industry Standard treatment Lymphoma Non-Hodgkin MALT lymphoma General Medicine Lymphoma B-Cell Marginal Zone medicine.disease biology.organism_classification Lymphoma Lymphatic system Oncology business Chemoradiotherapy Fluorescence in situ hybridization |
| Zdroj: | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 9(3) |
| ISSN: | 1436-3291 |
| Popis: | A 71-year-old man with a Helicobacter pylori infection-negative and API2-MALT1 translocation-negative extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type of the stomach has been followed conservatively for over 5 years. The lesion has shown no major morphological changes or malignant progression into a diffuse large-cell type during the time course. The absence of genetic translocation of API2-MALT1 was confirmed with fluorescence in situ hybridization (FISH). The prognosis of H. pylori-negative and API2-MALT1 translocation-negative low-grade MALT lymphoma is unknown, and a standard treatment for such lymphoma has yet to be defined. The case of MALT lymphoma negative for both of the above factors that we report has shown no obvious rapid progression or malignant change over the long-term course. Although curative operation and/or chemoradiotherapy should still be discussed as the treatment of choice, the treatment of this type of lymphoma must be carefully determined on a case-by-case basis, according to its biological status and prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink